tbuckley/cabot-search huggingface dataset:
Final Results of ECOG1100: A phase I/II study of combined blockade of the ErbB receptor network in patients with HER2- overexpressing metastatic breast cancer (MBC)
Authors: S. L. Moulder, A. O’Neill, C. Arteaga, M. Pins, J. Sparano, G. Sledge, N. Davidson
Journal: Journal of Clinical Oncology (2007)

1033 Background: Activation of EGF receptor has been associated with resistance to trastuzumab in breast cancer cell lines. EGFR tyrosine kinase inhibitors inhibit HER2 phosphorylation and synergize with trastuzumab in HER2+ cell lines that co-express EGFR. Methods: Pts with MBC and HER2 overexpression by immunohistochemistry (3+) and/or HER2 gene-amplification by FISH, 0–2 prior chemotherapy regimens for met disease, LVEF 50%, and no prior trastuzumab were treated with trastuzumab 2 mg/kg/wk and gefitinib 250- 500 mg/day until disease progression, unacceptable toxicity or withdrawal of consent. The phase I portion of the trial used a 3+3 design to determine MTD. In the phase II portion of the trial, patients were stratified based upon prior chemotherapy exposure (Group 1= no prior exposure to chemotherapy, Group 2= prior exposure to 1–2 chemotherapy regimens). Response measured using RECIST criteria. The primary endpoint was to increase proportion progression free from 50 to 65% at 6 months in Group 1 and from 50 to 70% at 3 months in Group 2. Results: Phase I: DLT (Grade 3 diarrhea) occurred in 2/3 patients treated at the 500 mg/day dose level of gefitinib in combination with weekly trastuzumab. 0/3 patients treated at the 250 mg/day dose level experienced DLT. This was considered MTD and was the dose selected for the Phase II portion of the trial. Phase II: 36 eligible pts were enrolled. Most patients were ECOG PS of 0 and had visceral organ involvement. Of the patients enrolled in Group 1, one pt achieved a CR, one PR and 7 had SD (≥ 24 weeks). Median time to progression (TTP) was 2.9 months (95% CI, 2.5–4). In Group 2 no responses were observed with a median TTP of 2.5 months (95% CI, 1.5- 2.7). Most common severe toxicities were rash (grade 3, 14%) and diarrhea (grade 3, 30%). No grade 3 cardiac toxicity was encountered. Conclusions: Trastuzumab in combination with gefitinib at doses of 250 mg/day demonstrated an acceptable toxicity profile; however, during planned interim analysis, the TTP did not meet predetermined statistical endpoints required for study continuation. These results do not support the further use of this combination and have implications for other trials using trastuzumab and EGFR TK inhibitors simultaneously. [Table: see text]
Can Bioethics Journals Become Role Models in Making Information, Data, Opinion, and Cross-Cultural Discussions Universally Available?
Authors: Sunil K. Pandya
Journal: The American Journal of Bioethics (2017)

"Can Bioethics Journals Become Role Models in Making Information, Data, Opinion, and Cross-Cultural Discussions Universally Available?." The American Journal of Bioethics, 17(10), pp. 31–32
LncRNA H19, HOTAIR and MALAT1 as prognostic molecular biomarkers in GIST
Authors: N. Barraco, L. Incorvaia, G. Badalamenti, F. Passiglia, A. Listì, R. Maragliano, E. Musso, E. Bronte, D. Cabibi, V. Calò, M. Castiglia, D. Fanale, A. Galvano, V. Gristina, S. Ingrao, L. Insalaco, D. Massihnia, A. Perez, V. Bazan, A. Russo
Journal: Annals of Oncology (2017)
Transforming Growth Factor-β1 Polarizes Murine Hematopoietic Progenitor Cells to Generate Langerhans Cell-Like Dendritic Cells Through a Monocyte/Macrophage Differentiation Pathway
Authors: Yi Zhang, Yan-yun Zhang, Masafumi Ogata, Pan Chen, Akihisa Harada, Shin-ichi Hashimoto, Kouji Matsushima
Journal: Blood (1999)
Phase I/II trial of weekly nab-paclitaxel as 2nd or 3rd line treatment in NSCLC without driver mutations. (OLCSG1303)
Authors: T. Ninomiya, K. Hotta, K. Ohashi, T. Kubo, D. Harada, T. Kozuki, N. Nogami, I. Oze, S. Hosokawa, A. Bessho, H. Yoshioka, K. Kudo, S. Kuyama, S. Harita, I. Takata, N. Fujimoto, T. Moritaka, H. Ichikawa, N. Takigawa, K. Kiura
Journal: Annals of Oncology (2017)
Risk factors of chemotherapy-induced nausea and vomiting during cisplatin regimen in antiemetic triplet regimen including palonosetron or granisetron: TRIPLE study (phase lll)
Authors: K. Suzuki, D. Tsuji, K. Ito, Y. Kawasaki, T. Yamanaka, H. Hashimoto, K. Goto, R. Matsui, N. Seki, T. Hama, N. Yamamoto
Journal: Annals of Oncology (2017)
Preliminary results from the new HIV surveillance system in France
Authors: F Lot, C Semaille, F Cazein, F Barin, R Pinget, J Pillonel, J C Desenclos
Journal: Eurosurveillance (2004)

In addition to AIDS surveillance, data on HIV infection are necessary to better follow the dynamics of the epidemic. We report the first results of France's mandatory anonymous HIV notification system, which is linked to a virological surveillance of recent HIV infections and of circulating HIV types, groups and subtypes. HIV notifications are initiated by microbiologists who create an anonymous code of patient's identity. Clinicians complete the notification form with epidemiological and clinical data. Notifications are sent to the local health authorities and passed to the Institut de Veille Sanitaire (InVS). Laboratories voluntarily send sera from newly diagnosed HIV infected persons on dried blood spots to the national HIV reference laboratory where an immunoassay for recent infection (< or = 6 months) and a serotyping assay for the determination of group and subtype are done. The virological results are then merged at the InVS with the information from the mandatory reporting. Of the first 1301 new HIV diagnoses reported in 2003, 43% were in women, and overall, 53% were in heterosexuals, of whom 47% were of sub-Saharan African origin. MSM accounted for 36% of male notifications. A dried blood spot was available for 64% of new HIV diagnoses. Evidence of recent infection was found for 38%, ranging from 22% in IDUs to 58% in MSM. Twenty-six percent of infections in sub-Saharan migrants were recent infections. HIV-1 accounted for 98% of all notifications: 48% of these were non-B subtypes. The first results of the HIV notification system indicate that heterosexual transmission is the predominant mode of transmission and that persons originating from sub-Saharan Africa are particularly affected. Over half of infections shown to be recently acquired were in MSM; this may indicate an increased HIV incidence in this population.
Epidémie de rougeole chez des adolescents, Belgique, 1996
Authors: K De Schrijver
Journal: Eurosurveillance (1996)

La rougeole est une maladie aigue tres contagieuse dont les signes sont : fievre, toux, coryza, conjonctivite, eruption d'un erytheme maculopapuleux et enantheme caracteristique (signe de Koplik). Des complications telles qu'une otite moyenne, une bronchopneumonie sont observees dans 10 % des cas. Une encephalite survient dans 1 cas sur 1 000. La frequence des complications de la rougeole augmente avec l'âge. Aux Etats-Unis, depuis 1989, on note trois deces sur 1000 cas declares (1).
Incident CKD after Radical or Partial Nephrectomy
Authors: John T. Leppert, Remy W. Lamberts, I-Chun Thomas, Benjamin I. Chung, Geoffrey A. Sonn, Eila C. Skinner, Todd H. Wagner, Glenn M. Chertow, James D. Brooks
Journal: Journal of the American Society of Nephrology (2017)

The comparative effectiveness of partial nephrectomy versus radical nephrectomy to preserve kidney function has not been well established. We determined the risk of clinically significant (stage 4 and higher) CKD after radical or partial nephrectomy among veterans treated for kidney cancer in the Veterans Health Administration (2001–2013). Among patients with preoperative eGFR≥30 ml/min per 1.73 m 2 , the incidence of CKD stage 4 or higher after radical ( n =9759) or partial nephrectomy ( n =4370) was 7.9% overall. The median time to stage 4 or higher CKD after surgery was 5 months, after which few patients progressed. In propensity score–matched cohorts, partial nephrectomy associated with a significantly lower relative risk of incident CKD stage 4 or higher (hazard ratio, 0.34; 95% confidence interval [95% CI], 0.26 to 0.43, versus radical nephrectomy). In a parallel analysis of patients with normal or near-normal preoperative kidney function (eGFR≥60 ml/min per 1.73 m 2 ), partial nephrectomy was also associated with a significantly lower relative risk of incident CKD stage 3b or higher (hazard ratio, 0.15; 95% CI, 0.11 to 0.19, versus radical nephrectomy) in propensity score–matched cohorts. Competing risk regression models produced consistent results. Finally, patients treated with a partial nephrectomy had reduced risk of mortality (hazard ratio, 0.55; 95% CI, 0.49 to 0.62). In conclusion, compared with radical nephrectomy, partial nephrectomy was associated with a marked reduction in the incidence of clinically significant CKD and with enhanced survival. Postoperative decline in kidney function occurred mainly in the first year after surgery and appeared stable over time.
Impact of cisplatin-based therapy on long-term survival in advanced urinary tract cancer (aUTC). A retrospective international study of invasive/advanced cancer of the urothelium (RISC)
Authors: A. Bamias, K. Tzannis, C. Bamia, L.C. Harshman, S. Crabb, Y-N. Wong, S.K. Pal, U. De Giorgi, S. Ladoire, N. Agarwal, E.Y. Yu, G. Niegisch, C.N. Sternberg, A. Srinivas, U. Vaishampayan, A. Necchi, J.E. Rosenberg, T. Powles, J. Bellmunt, M.D. Galsky
Journal: Annals of Oncology (2017)
Vigilância sentinela das doenças sexualmente transmissíveis em Itália
Authors: M Giuliani, B Suligoi
Journal: Eurosurveillance (1998)

As notificacoes obrigatorias sugerem que a incidencia da gonorreia e sifilis decresceram nos ultimos 30 anos em Italia, tal como em outros paises desenvolvidos (figura 1). No entanto, durante os anos 80, as taxas de notificacao em Italia foram 15 a 50 vezes mais baixas
Surto de triquiníase, na região de Midi-Pyrénées em França, Janeiro – Março de 1998
Authors: S Haeghebaert, M Servat, C Duchen, J C Minet, A EAgrech, I Thièse, C Leclerc, V Vaillant, C Hemery, E Maillot, C Soulé, E Pozio, P Massip, J. F. Magnaval, J C Desenclos
Journal: Eurosurveillance (1998)

Em 2 Marco de 1998, as autoridades de saude departamentais declararam, a Rede Nacional de Saude Publica (RNSP), dois surtos de triquiniase ocorridos nos departamentos de Tarn e Garonne em Franca. A 3 de Marco iniciou-se uma investigacao epidemiologica para determinar a extensao do surto, identificar a sua fonte e vector alimentar e propor medidas de controlo.
Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Authors: Vivek Subbiah, Juneko E. Grilley-Olson, Austin J. Combest, Neelesh Sharma, Richard H. Tran, Iulian Bobe, Atsushi Osada, Kazuhiro Takahashi, Jaikrishna Balkissoon, Aaron Camp, Atsuhiro Masada, Dirk J. Reitsma, Lyudmila A. Bazhenova
Journal: Clinical Cancer Research (2017)

Abstract Purpose: NC-6004, a novel cisplatin nanoparticle developed using micellar technology exhibits sustained release of cisplatin and selective distribution to tumors. Preclinical data demonstrated a favorable tolerability profile and preserved or improved antitumor activity compared with cisplatin across animal models. We evaluated the safety and tolerability of NC-6004 and gemcitabine using a Bayesian continual reassessment model (N-CRM) to determine the optimal dose. Experimental Design: Patients with advanced solid tumors received NC-6004 at 60 to 180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 began with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m2. Cohorts of four patients were enrolled at doses predicted by the N-CRM. The maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity &amp;lt;25%. Quality of life was assessed using EORTC-QLQ-C30. Results: Among 22 patients, the most common grade III/IV hematologic adverse events were leukopenia (68%) and thrombocytopenia (59%). Of 20 pretreated patients evaluable for response, half were previously exposed to a platinum agent. The MTD was 135 mg/m2. Nine patients were treated at the MTD with median treatment duration of 15 weeks (range, 3–50). Tumor shrinkage occurred in 11 (55%), partial responses in 3 (15%), and stable disease in 14 (70%). Most patients reported stable or improved EORTC QLQ-C30 scores. Conclusions: Greater cisplatin equivalent doses were achieved with no clinically significant neuro-, oto-, or nephrotoxicity. These data demonstrate tolerability and promising activity of NC-6004 in combination with gemcitabine. Clin Cancer Res; 24(1); 43–51. ©2017 AACR.
Nike+ Training Club, an ultimate personal trainer: mobile app user guide
Authors: Manolis Adamakis
Journal: British Journal of Sports Medicine (2017)

Figure 1 
Screenshots of Nike+ Training Club app user interface, showing: (A) the daily log history of a customisable workout plan; (B) the exercises available in the plan; (C) the personalised settings interface during an exercise.



Nike+ Training Club

Health and Fitness

Android (4.4 or later)—iOS (10.0 or later)

Free

Nike+ Training Club, which is a marketing tool for Nike, is an app for the deliverance of workouts and personalised adaptive training plans for a variety of physical activity levels. It is free of charge indefinitely after download in both Android and iOS platforms and has full and efficient functionality after downloading the selected video workouts through the app, which then can be used without ongoing data connection. No other additional software download is necessary, apart from the ordinary software updates.

Nike+ Training Club is designed to encourage and enhance physical activity by motivating and guiding individuals through a variety of activities. It has a neatly implemented interface set in a grey, black and white colour tone, which has a 15-min, 30-min and 45-min full-body workout training regimen. …
3-D MRI guided breast conserving surgery
Authors: K. Hisamatsu
Journal: Journal of Clinical Oncology (2007)

610 Background: In breast cancer patients, accurate diagnosis of ductal spreading is of great importanace for deciding sugical procedure. The role of imaging diagnosis using 3D-MRI in deciding of ductal spreading was assessed histologically and efficacy of 3D-MRI guided surgery was evaluated. Methods: Preoperative 3D-MRI was underwent 374 cases of breast cancer patients. Images were obtained 371 cases (99%). These patients could be divided into four groups according to 3D-MRI images: pattern 1) localized type, 2) widely enhanced type A (enhanced area: less than Quadrant) and 3) widely enhanced type B (enhanced area: more than Quadrant) and 4) multifocal type. Diagnosis of ductal spreading was confirmed histologically and relation between 3D-MRI patterns and ductal spreading were assessed retrospectively. Local failure of 3D-MRI guided surgery was assessed by 3D-MRI image patterns Results: The rate of histological confirmed ductal spreading were seen in 59% (125/212cases), 86% (49/57 cases) and 83% (19/23cases) of patients with 3D-MRI pattern 1), 2), and 3), respectively. From April 2005, resected specimen was serially step cut and total specimens were evaluated. Tumor diameter from nipple side to lateral margin were measured by MRI and resected specimens, tumor size was correlated between MRI and resected specimens, significantly (n=80, r=0.790887, P &lt; 0.001). Whole breast examination revealed that only 4 cases were multifocal cancer in 17 cases of multifocal image in 3D-MRI. Patient selection for breast conserving surgery was based by 3D-MRI images. The proportion of breast-conserved surgery were obtained 96% (203/212 cases), 86% (49/57 cases), 26% (6/23cases) and 89% (68/76 cases) of patients with 3D-MRI pattern 1), 2), 3), and 4), respectively. Local failures were seen 2cases in pattern 1), one case in 3) and one case in 4) (2–77 months, median follow up 39 months). Conclusions: These results suggest that MRI will be the useful breast imaging tool in diagnosing ductal spreading and tumor size in breast cancer patients. Safety breast conserving surgery was achieved by MRI guided surgery. No significant financial relationships to disclose.
A multicentre, phase II study with cabazitaxel in previously treated patients with advanced or metastatic adenocarcinoma of the oesophagogastric junction and stomach (CABAGAST)
Authors: T.O. Götze, S-E. Al-Batran, T. Zander, A. Reichart, U. Lindig, M. Kleiss, L. Mueller, C. Bolling, T. Seufferlein, P. Reichardt, F. Kullmann, H. Eschenburg, A. Schmittel, M. Egger, A. Block, C. Pauligk, H. Schmalenberg
Journal: Annals of Oncology (2017)
Pembrolizumab ± chemotherapy versus chemotherapy in advanced urothelial cancer: Phase 3 KEYNOTE-361 trial
Authors: T. Powles, J.E. Gschwend, Y. Loriot, J. Bellmunt, L. Geczi, C. Vulsteke, M. Abdelsalam, R. Gafanov, W.K. Bae, J. Revesz, Y. Yamamoto, U. Anido, W-P. Su, M. Fleming, M. Markus, D. Feng, C. Poehlein, A. Alva
Journal: Annals of Oncology (2017)
Cell Type-Specific Chromatin Signatures Underline Regulatory DNA Elements in Human Induced Pluripotent Stem Cells and Somatic Cells
Authors: Ming-Tao Zhao, Ning-Yi Shao, Shijun Hu, Ning Ma, Rajini Srinivasan, Fereshteh Jahanbani, Jaecheol Lee, Sophia L. Zhang, Michael P. Snyder, Joseph C. Wu
Journal: Circulation Research (2017)

Rationale: Regulatory DNA elements in the human genome play important roles in determining the transcriptional abundance and spatiotemporal gene expression during embryonic heart development and somatic cell reprogramming. It is not well known how chromatin marks in regulatory DNA elements are modulated to establish cell type–specific gene expression in the human heart. Objective: We aimed to decipher the cell type–specific epigenetic signatures in regulatory DNA elements and how they modulate heart-specific gene expression. Methods and Results: We profiled genome-wide transcriptional activity and a variety of epigenetic marks in the regulatory DNA elements using massive RNA-seq (n=12) and ChIP-seq (chromatin immunoprecipitation combined with high-throughput sequencing; n=84) in human endothelial cells (CD31 + CD144 + ), cardiac progenitor cells (Sca-1 + ), fibroblasts (DDR2 + ), and their respective induced pluripotent stem cells. We uncovered 2 classes of regulatory DNA elements: class I was identified with ubiquitous enhancer (H3K4me1) and promoter (H3K4me3) marks in all cell types, whereas class II was enriched with H3K4me1 and H3K4me3 in a cell type–specific manner. Both class I and class II regulatory elements exhibited stimulatory roles in nearby gene expression in a given cell type. However, class I promoters displayed more dominant regulatory effects on transcriptional abundance regardless of distal enhancers. Transcription factor network analysis indicated that human induced pluripotent stem cells and somatic cells from the heart selected their preferential regulatory elements to maintain cell type–specific gene expression. In addition, we validated the function of these enhancer elements in transgenic mouse embryos and human cells and identified a few enhancers that could possibly regulate the cardiac-specific gene expression. Conclusions: Given that a large number of genetic variants associated with human diseases are located in regulatory DNA elements, our study provides valuable resources for deciphering the epigenetic modulation of regulatory DNA elements that fine-tune spatiotemporal gene expression in human cardiac development and diseases.
First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
Authors: L. Zhang, Y. Huang, Y. Yang, S. Ma, X. Lin, L. Lin, T. Zhou, Y. Deng, C. Zhang, X. Ding, S. Wang, R. Wang, G. Feng, Y. Chen, R. Xu
Journal: Annals of Oncology (2017)
Authors' reply: Meningococcal disease in an ambulance worker
Authors: A Petsas, M Abid
Journal: Eurosurveillance (2008)

Fusco et al. raise some very interesting points regarding the spread of respiratory secretions in the form of aerosols caused by oxygen therapy. We believe this does indeed warrant further investigation, and a review of the guidelines regarding the chemoprophylaxis of staff involved in airway management.
Correlation of radiation pneumonitis history before nivolumab and onset risk of interstitial lung disease or progression free survival of nivolumab in patients with non-small cell lung cancer
Authors: A. Tamiya, M. Tamiya, K. Nakahama, Y. Taniguchi, T. Shiroyama, S.-I. Isa, T. Inoue, K. Nishino, T. Kumagai, H. Suzuki, T. Hirashima, F. Imamura, S. Atagi
Journal: Annals of Oncology (2017)
The Prevalence, Correlates, and Impact on Cardiac Mortality of Right Ventricular Dysfunction in Nonischemic Cardiomyopathy
Authors: Andreas Pueschner, Pairoj Chattranukulchai, John F. Heitner, Dipan J. Shah, Brenda Hayes, Wolfgang Rehwald, Michele A. Parker, Han W. Kim, Robert M. Judd, Raymond J. Kim, Igor Klem
Journal: JACC. Cardiovascular imaging (2017)
Un cas humain de rage liée aux voyages en Autriche, septembre 2004
Authors: R Strauss, A Gränz, M Wassermann-Neuhold, R Krause, Z Bago, S Revilla-Fernández, F Simón-Soria, J E Echevarria, T Popow-Kraupp, F Allerberger, M Schönbauer, H Hrabcik
Journal: Eurosurveillance (2005)

En juillet 2004, un jeune touriste autrichien de 23 ans,non vaccine contre la rage, a ete mordu par un chien au Maroc. Un mois plus tard, il etait hospitalise a Ceuta et presentait des symptomes compatibles avec la rage. Il est decede le 23 septembre a l’hopital en Autriche. Le diagnostic de rage a ete confirme par le test d’immunofluorescence et d’immunohistochimie et RT-PCR (avec sequencage) sur un echantillon de peau du cou et un prelevement pharynge. Ce cas autrichien de rage confirmee biologiquement souligne le besoin urgent de renforcer les recommandations internationales concernant les vaccinations liees aux voyages.
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma
Authors: Barbara Pro, Ranjana Advani, Pauline Brice, Nancy L. Bartlett, Joseph D. Rosenblatt, Tim Illidge, Jeffrey Matous, Radhakrishnan Ramchandren, Michelle Fanale, Joseph M. Connors, Keenan Fenton, Dirk Huebner, Juan M. Pinelli, Dana A. Kennedy, Andrei Shustov
Journal: Blood (2017)
Abstract 16190: Incidence and Outcomes of Patients Hospitalized With Myocardial Infarction and Co-existing Cerebrovascular Accident in United States
Authors: Saurabh Aggarwal, Rohit S Loomba, Gaurav Aggarwal, Navdeep Gupta, Manu Kaushik, Aryan Mooss, Michael White, Rohit Arora, Venkata Alla
Journal: Circulation (2016)

Introduction:  Patients with myocardial infarction (MI) are at a higher risk of both ischemic and hemorrhagic cerebrovascular accidents (CVA). Data regarding trends and outcomes of patients hospitalized with MI and coexisting CVA remain scant.   Hypothesis:  Patients with MI with coexisting CVA have higher length and cost of hospitalization and higher in-hospital mortality compared to those without CVA.   Methods:  We assessed the incidence, trends and outcomes in patients with MI who had a CVA and compared this to patients with MI who did not have a CVA by utilizing nationwide inpatient sample database. Individual trends and outcomes of subarachnoid hemorrhage (SAH), hemorrhagic stroke (HS) and ischemic stroke (IS) were also assessed in patients with MI.   Results:  A total of 550,849 patients with a diagnosis of myocardial infarction were included in the analysis, out of which 84,981 patients had a coexisting diagnosis of CVA. The number of patients with coexisting MI and CVA increased significantly from 2005 to 2012 (10% vs 20%, p   Conclusion:  The rates of CVA in patients with MI have increased significantly in the United States. CVA is associated with a longer and costlier hospital stay and a higher in-hospital mortality in patients with MI.